Premium
Antimetastatic Effects of Licochalcone B on Human Bladder Carcinoma T24 by Inhibition of Matrix Metalloproteinases‐9 and NF ‐к B Activity
Author(s) -
Zhao Hong,
Yuan Xuan,
Jiang Jiangtao,
Wang Penglong,
Sun Xiling,
Wang Dong,
Zheng Qiusheng
Publication year - 2014
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/bcpt.12273
Subject(s) - matrix metalloproteinase , microbiology and biotechnology , chemistry , zymography , viability assay , western blot , matrigel , iκbα , nf κb , cell , cancer research , biology , biochemistry , signal transduction , gene
This study investigated the mechanisms by which licochalcone B (LCB) inhibits the adhesion,invasion and metastasis of human malignant bladder cancer T24 cells. Cell viability was evaluated using a sulforhodamine B (SRB) assay. Cell migration and invasion ability were conducted using wound‐healing assay and matrigel transwell invasion assay. The activities of matrix metalloproteinases (MMP)‐2 and MMP‐9 were measured by gelatin zymography protease assays. The expression in protein level of NF‐κBP65 and AP‐1 was determined using the ELISA method; the protein levels of MMP‐9, NF‐κBP65, IκBα and P‐IκBα were detected by Western blot. The expression in m RNA level of MMP‐9 was assessed using quantitative real‐time polymerase chain reaction (PCR) and reverse transcription PCR. The results indicated that LCB attenuated T24 cell migration, adhesion and invasion in a concentration‐dependent manner. LCB treatment down‐regulated the m RNA expression, protein expression and activity of MMP‐9 but had no effect on MMP‐2. In addition, LCB treatment decreased the protein level of NF‐кBP65 and nuclear translocation of NF‐кB. These findings suggested that LCB attenuated migration of bladder cancer T24 cells and adhesion and invasion accompanied with down‐regulated protein expression of MMP‐9 and the nuclear translocation of NF‐кB. Our results provide support that LCB may be a potent adjuvant therapeutic agent in the prevention and therapy of bladder cancer.